Clinical bottom line
Enthesitis-related arthritis (ERA) in pediatric patients often proves refractory to conventional therapies, posing a significant challenge in clinical management. Emerging evidence supports the efficacy and safety of anti-TNF agents, particularly adalimumab, in improving clinical outcomes for children with refractory ERA. While these biologics offer promising therapeutic options, careful patient selection and monitoring remain essential due to limited long-term data and variability in response. This digest summarizes current evidence on novel therapies for refractory ERA in pediatric populations, highlighting their potential to enhance disease control and functional status.
What the evidence shows
ERA is a subtype of juvenile idiopathic arthritis characterized by inflammation at entheses and peripheral joints, frequently associated with HLA-B27 positivity and a risk of chronic disease and joint damage (Tse et al., 2016). Conventional treatments including NSAIDs and DMARDs often fail to achieve sustained remission in refractory cases, prompting investigation into biologic therapies.
Anti-TNF agents, particularly adalimumab, have been evaluated in pediatric ERA with encouraging results. The PReS-FINAL-2179 study (Burgos-Vargas et al., 2013) demonstrated that adalimumab significantly improved clinical signs and symptoms in children with ERA refractory to conventional DMARDs. Similarly, Burgos-Vargas et al. (2014) reported sustained efficacy and an acceptable safety profile of adalimumab in this population, supporting its role as a viable treatment option.
Earlier observational data from Tynjälä et al. (2008) also indicated that anti-TNF therapy reduces disease activity and improves functional outcomes in ERA patients, although this study included a broader juvenile arthritis cohort. Sarma et al. (2008) highlighted the importance of early and effective intervention to prevent long-term joint damage and functional impairment, underscoring the potential impact of biologics in modifying disease trajectory.
Collectively, these studies suggest that anti-TNF agents can achieve meaningful clinical improvement in refractory ERA, including reduction in enthesitis, arthritis, and systemic inflammation, with an acceptable safety profile in pediatric patients.
Caveats and uncertainty
Despite promising data, several uncertainties remain. Most evidence derives from open-label trials or observational cohorts with relatively small sample sizes and limited follow-up duration, restricting conclusions about long-term safety and durability of response. Pediatric ERA is heterogeneous, and predictors of response to biologics are not well defined, complicating individualized treatment decisions.
The risk of infections and other adverse events associated with anti-TNF therapy necessitates vigilant monitoring, especially in children. Comparative effectiveness versus other biologics or emerging targeted therapies has not been extensively studied in ERA. Furthermore, data on optimal timing, dosing, and tapering strategies for biologics in pediatric ERA are sparse.
Finally, while adalimumab is the most studied agent, evidence for other biologics or novel therapies in ERA remains limited, warranting further investigation.
How this may change practice
For pediatric rheumatologists managing refractory ERA, anti-TNF agents, particularly adalimumab, represent a valuable addition to the therapeutic armamentarium. Incorporating these biologics earlier in the treatment algorithm may improve disease control, reduce joint damage, and enhance quality of life.
Clinicians should weigh benefits against potential risks, engage in shared decision-making with patients and families, and implement rigorous monitoring protocols. Awareness of current evidence can guide appropriate patient selection and optimize treatment outcomes.
Ongoing research and real-world registries will be critical to refine treatment strategies, identify biomarkers of response, and expand therapeutic options beyond anti-TNF agents.